Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort

Acumen Pharmaceuticals, Inc.

Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.
Golumbeski received initial option to buy 50,000 shares at closing price, vesting over 3 years.
Annual retainer: $40,000 for board service plus $30,000 as Chairman.
Board now has 8 members; Golumbeski brings 30+ years biopharma experience from Celgene, Novartis.
Company highlights Phase 2 sabirnetug trial and Enhanced Brain Delivery program as key 2026 catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.